Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.34 USD | +5.33% | +2.47% | -26.06% |
Apr. 15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- With an enterprise value anticipated at 3.35 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company is highly valued given the cash flows generated by its activity.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-26.06% | 1.55B | C+ | ||
-20.55% | 10.81B | A- | ||
+47.97% | 3.36B | D+ | ||
-32.75% | 2.22B | C | ||
-14.15% | 2.16B | - | B- | |
+19.85% | 1.04B | B- | ||
-2.62% | 746M | C+ | ||
-31.67% | 425M | C- | ||
-43.88% | 405M | C- | ||
+29.03% | 378M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VCYT Stock
- Ratings Veracyte, Inc.